AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Safe. DYOR

Meint ihr das wird noch was?

Hatte 0 Auswirkungen auf den Kurs.

Was eine Geldverschwendungsanlage

AbCellera Biologics Inc. gab bekannt, dass Peter Thiel das Unternehmen über seine Absicht informiert hat, aus persönlichen Gründen mit Wirkung zum 7. März 2024 aus dem Verwaltungsrat des Unternehmens auszuscheiden. Herr Thiel trat dem Verwaltungsrat von AbCellera im November 2020 bei und war Vorsitzender des Nominierungs- und Corporate Governance-Ausschusses des Unternehmens. Mit Wirkung vom 7. März 2024 wird Dr. Andrew Lo, ein Mitglied des Verwaltungsrats des Unternehmens, in den Nominierungs- und Corporate Governance-Ausschuss des Verwaltungsrats berufen. Herr Thiel hat das Unternehmen nicht über Meinungsverschiedenheiten mit dem Unternehmen in Bezug auf seine Geschäftstätigkeit, Politik oder Praktiken informiert. Mit dem Rücktritt von Herrn Thiel als Verwaltungsratsmitglied wird die Größe des Verwaltungsrats der Gesellschaft von sechs auf fünf Mitglieder reduziert

Good bye abcellera

Thiel ist als Vorstand bei Abcellera zurück getreten.

02/22/2024 ABCL Buy Now AbCellera Biologics $5.08 — Benchmark Robert Wasserman — Upgrade Hold → Buy

Ryan Adist Ryan Adist Feb 21, 2024, 02:14 PM Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) today and set a price target of $17.00. The company’s shares closed yesterday at $5.31. According to TipRanks, Willey is a 5-star analyst with an average return of 10.3% and a 43.16% success rate. Willey covers the Healthcare sector, focusing on stocks such as Exelixis, Compugen, and Incyte. The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $12.33 average price target, representing a 132.20% upside. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $12.00 price target.

2025 wird das HQ in Vancouver fertig gestellt.

Das Volumen hat gefehlt. Gebe Bescheid wenn wir mit ordentlich Volumen drüber sind und stark abschließen.

Sollte ich mein Geld eines Tages wieder haben verkaufe ich sofort diesen Müll

Es gab eine sogenannte „positive“ Meinung von Motley Fool, die die Langfristigkeit und das Risiko betonte. Danke schön. '1. AbCellera Biologics (ABCL -5.29%), a Canadian biotech, focuses on developing antibody-based medicines. The drugmaker's stock price has plummeted by more than 90% since it went public in late 2020, reflecting the risk-averse environment of the broader markets over this period. However, some analysts believe that AbCellera's stock could bounce back by a whopping 212% in 2024. The main reason for this bullish outlook is the potential for AbCellera to secure one or more major collaboration deals soon. Still, AbCellera is an extremely risky investment because the company does not expect to start clinical trials for its two most advanced programs -- ABCL575 and ABCL635 -- until 2025. Patient investors, though, might be richly rewarded by buying and holding this antibody drug specialist for the long haul. After all, antibody-based medicines represent one of the largest and fastest growing segments of biopharmaceutical industry right now.'

Haben wir erreicht und fällt trotzdem wieder stark

BMO Capital analyst Evan Seigerman has reiterated their bullish stance on ABCL stock, giving a Buy rating on January 5. Evan Seigerman has given his Buy rating due to a combination of factors surrounding AbCellera Biologics’s prospects and strategies. Despite not securing a partner for their T-cell engager (TCE) program in 2023, management has a strong conviction that a partnership will be forged in 2024, based on the impressive capabilities of their TCE assets and the demonstrated interest from the pharmaceutical industry in such technologies. Seigerman’s confidence stems from the fact that there has been a trend towards acquisitions and development of TCE assets by major pharmaceutical companies, which suggests a favorable environment for AbCellera to enter into a lucrative deal. Furthermore, the focus on internal pipeline updates, particularly for ABCL575 and ‘635, is anticipated to be a major catalyst for the company. The shift in strategy to prioritize the advancement of internal assets has been viewed positively by Seigerman, as it has the potential to significantly enhance shareholder value. While breakthroughs in AI drug development are considered an important aspect of the company’s future, the expectation is that these will take longer to materialize, suggesting a more measured but persistent approach to innovation. In another report released on January 5, KeyBanc also maintained a Buy rating on the stock with a $8.00 price target. https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-abcellera-biologics-amid-positive-tce-program-prospects-and-strategic-pipeline-focus?mod=mw_quote_news#google_vignette